Table 4.
Serum resistin, visfatin and chemerin concentrations and their ratios in T2DM patients and controls.
| Resistin(ng/mL) | Visfatin(ng/mL) | Chemerin (ng/mL) | |||||
|---|---|---|---|---|---|---|---|
| Gender | Females | Males | Females | Males | Females | ||
| Groups | |||||||
| Controls | 22.86 ± 4.88 | 24.32 ± 4.94 | 3.82 ± 1.74 | 3.16 ± 1.62 | 268.42 ± 54.23 | 262.13 ± 54.03 | |
| A | 24.54 ± 4.85 | 25.21 ± 4.90 | 6.45 ± 2.13 * | 5.44 ± 1.86 | 272.12 ± 54.69 | 267.72 ± 54.11 | |
| B | 22.45 ± 4.12 | 20.32 ± 4.04 | 6.62 ± 2.15 * | 6.12 ± 1.91 | 279.35 ± 55.12 | 275.32 ± 54.89 | |
| C | 28.76 ± 6.04 | 29.43 ± 5.98 | 6.92 ± 2.34 ** | 8.12 ± 2.32 ***# | 298.65 ± 56.34 * | 292.45 ± 55.12 * | |
| D | 26.98 ± 5.94 | 31.32 ± 0.45 | 7.1 ± 2.54 ** | 7.48 ± 2.56 **# | 323.43 ± 58.23 **# | 299.12 ± 57.03 ** | |
Group A—T2DM patients with normal body weight; group B—overweight T2DM patients; group C—T2DM patients with obesity and group D—T2DM patients with severe obesity. * p < 0.05 vs. controls; ** p < 0.01 vs. controls; *** p < 0.001 vs. controls, # p < 0.05 vs. groups A and B.